Genmab — Maj 2019

[peter12]

Marshall Wace LLP holds a short position at 0.54 % in shares issued by Genmab A/S

[E_L]

New trial : Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE) - https://clinicaltrials.gov/ct2/show/NCT03942224

[peter12]

De har nok skumle planer ...

[E_L]

I actually thought Ixazomib and bortezomib are sort of similar, both proteasome inhibitors , did not expect them to be used together

[Plimsoller]

Siden findes ikke

(borsen.dk)

[ienk1]

Marshall Wace LLP has reduced his short position to 303580 shares issued by Genmab A/S 14/02 2019

[Bulder]

E L, you can see the explanation in experimental arm II. They don't get isa and bor at the same time.

[E_L]

ok, thks, i see it now

[Bulder]

+6 kroner på en lukkeauktion. Det er vist rekord.

[Helge_LarsenPI-redaktør]

[E_L]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-quarter-2019

[jkj]

nøgletal lidt dårligere end forventet

[jkj]

Den skal tales godt op til q&A ellers er der ingen belønning.

[Helge_LarsenPI-redaktør]

Regnskabet er inden for skiven.

[jkj]

jeg syndes det er skræmmende at cashburn er blevet så stort at der ikke kan laves et plus.

[E_L]

so if they had slowed down their work and hiring just to get a small plus you would have been happier...?

[Legolas23]

Børsen i vanlig prosa

[Legolas23]

Siden findes ikke

(borsen.dk)

[Legolas23]

Finans.dk https://finans.dk/erhverv/ECE11367987/genmabs-sats-paa-fremtiden-koster-dyrt-faa-overblikket-her/?ctxref=forside

[jkj]

Det kort svar EL er ja, og jeg er næppe alene med den holdning.